论文部分内容阅读
目的 探讨三组自体造血干细胞移植疗效及影响疗效因素 ,与同期化疗组疗效比较。方法 对未净化自体骨髓移植 (ABMT) 17例、净化自体骨髓移植 (PABMT) 30例、自体外周血干细胞移植 (APBHSCT) 5 5例、同期化疗组 34例 ,进行临床资料分析。结果 ABMT组、PABMT组、APBHSCT组 3年无病生存 (DFS)率及复发率分别为 6 3 8%、70 4% ;6 6 5 %、35 2 % ;2 6 6 %、2 9 5 %。骨髓恢复增生活跃中位时间分别为 6 0d、5 8d、34d。影响疗效因素 :AML疗效优于ALL疗效 ,CR1期移植优于CR2 期移植 ,CR到移植期间 >7个月者优于 <7个月者。化疗组 3年DFS为 7 38% ,复发率为 76 4%。结论 PABMT组疗效优于其它二组 ,APBHSCT组造血功能恢复较其它二组快 ,AML疗效优于ALL疗效 ,CR1期移植优于CR2 期移植 ,3个移植组疗效优于化疗组。
Objective To investigate the curative effect of three groups of autologous hematopoietic stem cell transplantation and the factors that affect curative effect compared with the same period of chemotherapy group. Methods 17 cases of unprocessed autologous bone marrow transplantation (ABMT), 30 cases of autologous bone marrow transplantation (PABMT), 55 cases of autologous peripheral blood stem cell transplantation (APBHSCT) and 34 cases of chemotherapy in the same period were performed clinical data analysis. Results The 3-year disease-free survival (DFS) and recurrence rates of ABMT, PABMT and APBHSCT were 63.8% and 70.4%, 66.5% and 35.2%, 26.6% and 25.5% . Median bone marrow recovery hyperplasia time were 60d, 58d, 34d. Affect the efficacy of factors: AML curative effect is superior to ALL curative effect, CR1 phase transplantation is better than CR2 phase transplantation, CR> 7 months after transplantation was better than <7 months. Three-year DFS in chemotherapy group was 73.8%, and the recurrence rate was 76.4%. Conclusions The efficacy of PABMT is better than that of the other two groups. The hematopoietic recovery of APBHSCT group is faster than that of the other two groups. The efficacy of AML is better than that of ALL. The CR1 graft is better than CR2 graft. The efficacy of three transplantation groups is better than that of chemotherapy group.